BioNTech claims a FixVac win
But the company hasn’t given details, and used a historical control rather than the study’s own control arm.
Roche’s Skyscraper looks on shaky foundations
Roche curbs its TIGIT push, while a co-stimulation crunch could be bad news for Regeneron.
ESMO 2024 preview – Astellas unveils its KRAS degrader
ASP3082 grabs some early attention among degraders set to feature at ESMO.
ESMO 2024 preview – conjugates in the spotlight
Early attention falls on ADCs originated by ProfoundBio, SystImmune, MediLink and Seagen.
Novartis drops out of KRAS
While Roche, Lilly and Merck push on aggressively, Novartis throws in the towel.
The Revolution is here, and it’s... confusing
The group reaffirms pancreatic cancer promise with RMC-6236, but has it found the best dose?
